Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018752 | 0.92 | CA2 (0.39) | CA2LTA4HLMNASMN1; SMN2NR1D1 | |
| SCHEMBL1018053 | 0.82 | LTA4H (0.40) | CA2LTA4HLMNASMN1; SMN2KDM4E | |
| SCHEMBL1021465 | 0.82 | KDM4E (0.49) | CA2LTA4HLMNASMN1; SMN2KDM4E | |
| SCHEMBL1885058 | 0.75 | CA2 (0.40) | CA2 | |
| SCHEMBL1019554 | 0.75 | LTA4H (0.34) | CA2LTA4HLMNASMN1; SMN2NR1D1 | |
| SCHEMBL1019545 | 0.73 | KDM4E (0.41) | CA2LTA4HLMNASMN1; SMN2KDM4E | |
| SCHEMBL22204407 | 0.69 | KDM4E (0.46) | LTA4HKDM4EMAOBL3MBTL1 | |
| SCHEMBL1882834 | 0.69 | LMNA (0.50) | CA2LMNASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6855950 | 0.67 | DRD2 (0.39) | CA2LMNANR1D1ALDH1A1ALOX5 | |
| SCHEMBL1884190 | 0.65 | CA2 (0.39) | CA2LMNASMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | CA2 3728/4885LTA4H 1989/4885LMNA 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.